Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins

Abstract The safety and efficacy of several life-saving therapeutic proteins are compromised due to their immunogenicity. Once a sustained immune response against a protein-based therapy is established, clinical options that are safe and cost-effective become limited. Prevention of immunogenicity of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nhan H. Nguyen, Fiona Y. Glassman, Robert K. Dingman, Gautam N. Shenoy, Elizabeth A. Wohlfert, Jason G. Kay, Richard B. Bankert, Sathy V. Balu-Iyer
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1786baa1e47743e4a012fbcf4ceadcfd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1786baa1e47743e4a012fbcf4ceadcfd
record_format	dspace
spelling	oai:doaj.org-article:1786baa1e47743e4a012fbcf4ceadcfd2021-12-02T14:58:47ZRational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins10.1038/s41598-021-97333-02045-2322https://doaj.org/article/1786baa1e47743e4a012fbcf4ceadcfd2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97333-0https://doaj.org/toc/2045-2322Abstract The safety and efficacy of several life-saving therapeutic proteins are compromised due to their immunogenicity. Once a sustained immune response against a protein-based therapy is established, clinical options that are safe and cost-effective become limited. Prevention of immunogenicity of therapeutic proteins prior to their initial use is critical as it is often difficult to reverse an established immune response. Here, we discuss a rational design and testing of a phosphatidylserine-containing nanoparticle platform for novel oral prophylactic reverse vaccination approach, i.e., pre-treatment of a therapeutic protein in the presence of nanoparticles to prevent immunogenicity of protein therapies.Nhan H. NguyenFiona Y. GlassmanRobert K. DingmanGautam N. ShenoyElizabeth A. WohlfertJason G. KayRichard B. BankertSathy V. Balu-IyerNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Nhan H. Nguyen Fiona Y. Glassman Robert K. Dingman Gautam N. Shenoy Elizabeth A. Wohlfert Jason G. Kay Richard B. Bankert Sathy V. Balu-Iyer Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins
description	Abstract The safety and efficacy of several life-saving therapeutic proteins are compromised due to their immunogenicity. Once a sustained immune response against a protein-based therapy is established, clinical options that are safe and cost-effective become limited. Prevention of immunogenicity of therapeutic proteins prior to their initial use is critical as it is often difficult to reverse an established immune response. Here, we discuss a rational design and testing of a phosphatidylserine-containing nanoparticle platform for novel oral prophylactic reverse vaccination approach, i.e., pre-treatment of a therapeutic protein in the presence of nanoparticles to prevent immunogenicity of protein therapies.
format	article
author	Nhan H. Nguyen Fiona Y. Glassman Robert K. Dingman Gautam N. Shenoy Elizabeth A. Wohlfert Jason G. Kay Richard B. Bankert Sathy V. Balu-Iyer
author_facet	Nhan H. Nguyen Fiona Y. Glassman Robert K. Dingman Gautam N. Shenoy Elizabeth A. Wohlfert Jason G. Kay Richard B. Bankert Sathy V. Balu-Iyer
author_sort	Nhan H. Nguyen
title	Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins
title_short	Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins
title_full	Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins
title_fullStr	Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins
title_full_unstemmed	Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins
title_sort	rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/1786baa1e47743e4a012fbcf4ceadcfd
work_keys_str_mv	AT nhanhnguyen rationaldesignofananoparticleplatformfororalprophylacticimmunotherapytopreventimmunogenicityoftherapeuticproteins AT fionayglassman rationaldesignofananoparticleplatformfororalprophylacticimmunotherapytopreventimmunogenicityoftherapeuticproteins AT robertkdingman rationaldesignofananoparticleplatformfororalprophylacticimmunotherapytopreventimmunogenicityoftherapeuticproteins AT gautamnshenoy rationaldesignofananoparticleplatformfororalprophylacticimmunotherapytopreventimmunogenicityoftherapeuticproteins AT elizabethawohlfert rationaldesignofananoparticleplatformfororalprophylacticimmunotherapytopreventimmunogenicityoftherapeuticproteins AT jasongkay rationaldesignofananoparticleplatformfororalprophylacticimmunotherapytopreventimmunogenicityoftherapeuticproteins AT richardbbankert rationaldesignofananoparticleplatformfororalprophylacticimmunotherapytopreventimmunogenicityoftherapeuticproteins AT sathyvbaluiyer rationaldesignofananoparticleplatformfororalprophylacticimmunotherapytopreventimmunogenicityoftherapeuticproteins
_version_	1718389247914803200

Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins

Ejemplares similares